Review
SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health
Paul Van Caeseele, for the Canadian Public Health Laboratory Network, Dana Bailey, for the Canadian Society of Clinical Chemists, Sarah E. Forgie, for the Association of Medical Microbiology and Infectious Disease Canada, Tanis C. Dingle, for the Canadian Association for Clinical Microbiology and Infectious Diseases, Mel Krajden and for the COVID-19 Immunity Task Force
CMAJ August 24, 2020 192 (34) E973-E979; DOI: https://doi.org/10.1503/cmaj.201588
Paul Van Caeseele
Cadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
MDCadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
Dana Bailey
Cadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
MSc PhDCadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
Sarah E. Forgie
Cadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
MD MEdCadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
Tanis C. Dingle
Cadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
PhDCadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
Mel Krajden
Cadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
MDCadham Provincial Public Health Laboratory (Van Caeseele), Winnipeg, Man.; Dynacare (Bailey), Brampton, Ont.; Division of Pediatric Infectious Diseases (Forgie), Department of Pediatrics, University of Alberta, Edmonton, Alta.; Alberta Precision Laboratories (Dingle), Edmonton, Alta.; and Department of Pathology and Laboratory Medicine (Krajden), University of British Columbia, Vancouver, BC.
Data supplements
Earn CPD Credits
This article is eligible for 0.5 Mainpro+ credits.
Did you read this article?
Note: The YES link above may not work in certain versions of Internet Explorer 8. If you are having difficulties with this link, please try another browser.
Related Articles
- Van Caeseele, P., Bailey, D., Forgie, S. E., , ., & Dingle, T. C. (2020). Sérologie du SRAS-CoV-2 (COVID-19) : Répercussions sur la pratique clinique, la médecine de laboratoire et la santé publique. CMAJ, 192(49), E1776-E1782. Accessed April 18, 2024. https://doi.org/10.1503/cmaj.201588-f.
In this issue
Article tools
Respond to this article
SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health
Paul Van Caeseele, for the Canadian Public Health Laboratory Network, Dana Bailey, for the Canadian Society of Clinical Chemists, Sarah E. Forgie, for the Association of Medical Microbiology and Infectious Disease Canada, Tanis C. Dingle, for the Canadian Association for Clinical Microbiology and Infectious Diseases, Mel Krajden, for the COVID-19 Immunity Task Force
CMAJ Aug 2020, 192 (34) E973-E979; DOI: 10.1503/cmaj.201588
SARS-CoV-2 (COVID-19) serology: implications for clinical practice, laboratory medicine and public health
Paul Van Caeseele, for the Canadian Public Health Laboratory Network, Dana Bailey, for the Canadian Society of Clinical Chemists, Sarah E. Forgie, for the Association of Medical Microbiology and Infectious Disease Canada, Tanis C. Dingle, for the Canadian Association for Clinical Microbiology and Infectious Diseases, Mel Krajden, for the COVID-19 Immunity Task Force
CMAJ Aug 2020, 192 (34) E973-E979; DOI: 10.1503/cmaj.201588
Jump to section
Related Articles
Cited By...
- Clinical performance of a chemiluminescence SARS-CoV-2 antibody assay in a cohort of healthcare workers, blood donors and COVID-19 patients
- Predictors of severe illness in children with multisystem inflammatory syndrome after SARS-CoV-2 infection: a multicentre cohort study
- A scalable serology solution for profiling humoral immune responses to SARS-CoV-2 infection and vaccination
- Specificity of SARS-CoV-2 antibody-detection assays against S and N protein among pre-COVID-19 sera from patients with protozoan and helminth parasitic infections
- Current challenges of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seroprevalence studies among blood donors: A scoping review
- Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection
- Detection of SARS-CoV-2 antibodies formed in response to the BNT162b2 and mRNA-1237 mRNA vaccine by commercial antibody tests
- Quantitative Measurement of Anti-SARS-CoV-2 Antibodies: Analytical and Clinical Evaluation
- Evaluation of a Commercial Culture-free Neutralization Antibody Detection Kit for Severe Acute Respiratory Syndrome-Related Coronavirus-2 and Comparison with an Anti-RBD ELISA Assay
- Analytical and clinical evaluation of four anti-SARS-CoV-2 serologic (IgM, IgG, and total) immunoassays